Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Benzinga

Feb 17

Complement-mediated diseases arise from overactivation or dysfunction of the complement system, a part of the innate immune system. The Phase 1 study results demonstrated complete and sustained ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612659234"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612659234\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612659234?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/17/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2026-02-17 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612659234","market":"us","top_or_hot":-1,"title":"Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026","media":"Benzinga","content":"<div>\n<p>Complement-mediated diseases arise from overactivation or dysfunction of the complement system, a part of the innate immune system.\nThe Phase 1 study results demonstrated complete and sustained ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50655870/rallybio-shares-successful-early-stage-results-for-rare-disease-drug-new-trial-set-for-late-2026\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-17 23:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/02/50655870/rallybio-shares-successful-early-stage-results-for-rare-disease-drug-new-trial-set-for-late-2026><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Complement-mediated diseases arise from overactivation or dysfunction of the complement system, a part of the innate immune system.\nThe Phase 1 study results demonstrated complete and sustained ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50655870/rallybio-shares-successful-early-stage-results-for-rare-disease-drug-new-trial-set-for-late-2026\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/02/50655870/rallybio-shares-successful-early-stage-results-for-rare-disease-drug-new-trial-set-for-late-2026","article_id":"2612659234","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/17/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/02/50655870/rallybio-shares-successful-early-stage-results-for-rare-disease-drug-new-trial-set-for-late-2026","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612659234","pubTimestamp":1771343160,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Rallybio reports strong Phase 1 results for RLYB116, showing full immune pathway control with good safety and Phase 2 plans ahead.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","SMA":"Smartstop Self Storage REIT Inc","RLYB":"Rallybio Corp.","BK4139":"生物科技","SSI":"Stage Stores Inc","BK4217":"自存仓储房地产信托"},"translate_title":"Rallybio分享罕见病药物的成功早期结果；新试验定于2026年底进行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLYB":1.5,"SMA":1,"SSI":1.5},"content_text":"Complement-mediated diseases arise from overactivation or dysfunction of the complement system, a part of the innate immune system.\nThe Phase 1 study results demonstrated complete and sustained inhibition of terminal complement at a 300 mg dose, with a safety profile consistent with other subcutaneous biologics.\nComplete and sustained inhibition of ex vivo hemolytic activity demonstrates clinically effective blockade of terminal complement.\nIn the study, RLYB116 showed promising pharmacokinetic and pharmacodynamic results.\nRLYB116 administered as a 150 mg and 300 mg once-a-week dose was well tolerated with no gastrointestinal side effects reported among participants.\nThe most common adverse events in both cohorts were mild-to-moderate injection site reactions, consistent with other subcutaneously administered biologics.\nNone were severe or caused discontinuation of the study drug.\nRallybio plans to initiate a Phase 2 clinical trial for immune platelet transfusion refractoriness in the second half of 2026, with topline data expected in 2027.\nCurrently, Rallybio is trading 4.5% below its 20-day simple moving average (SMA) and 8.2% below its 100-day SMA, indicating bearish momentum in the short to medium term. Shares have decreased 17.97% over the past 12 months and are positioned closer to their 52-week lows than highs.\nThe RSI is at a neutral level, indicating that the stock is neither overbought nor oversold at this time. Meanwhile, the MACD is below its signal line, suggesting bearish pressure on the stock.\nThe combination of neutral RSI and bearish MACD indicates mixed momentum for Rallybio, reflecting uncertainty in the stock’s near-term direction.\nRallybio is part of the healthcare sector, which is currently ranked 5 out of 11 sectors, reflecting a mid-tier performance. \nOver the past 30 days, the healthcare sector has seen a modest increase of 1.46%, and over the last 90 days, it has risen by 3.51%. This context highlights that while the sector is experiencing some upward momentum, Rallybio’s recent performance has not mirrored this trend.\nBelow is the Benzinga Edge scorecard for Rallybio, highlighting its strengths and weaknesses compared to the broader market:\nRLYB Price Action: Rallybio shares were down 6.64% at $4.50 at the time of publication on Tuesday, according to Benzinga Pro data.\nPhoto: Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}